DVT Prophylaxis Recommendations

Standard Prophylactic Dosing Options

• The American Society of Clinical Oncology recommends enoxaparin 40 mg subcutaneously once daily or unfractionated heparin (UFH) 5000 IU subcutaneously every 8 hours for DVT prophylaxis, with selection based on patient factors and clinical context 1, 2
• The National Comprehensive Cancer Network recommends dalteparin 5000 IU subcutaneously once daily as an alternative option for DVT prophylaxis 2
• Tinzaparin 4500 IU or 75 IU/kg subcutaneously once daily is also recommended for DVT prophylaxis 2

Unfractionated Heparin (UFH) Dosing

• The National Comprehensive Cancer Network recommends UFH 5000 IU subcutaneously every 8 hours, which is preferred in cancer patients 3, 4, 2
• UFH administered 3 times daily was shown to be more effective than twice-daily dosing in preventing DVT in general surgery patients 3

Duration of Prophylaxis

• The American College of Cardiology recommends continuing DVT prophylaxis until fully ambulatory or hospital discharge for medical patients 1
• Surgical patients should receive DVT prophylaxis for at least 7-10 days 1
• Cancer patients should consider extended DVT prophylaxis, especially with ongoing risk factors 2

Special Population Considerations

Renal Impairment

• For patients with creatinine clearance <30 mL/min, the National Comprehensive Cancer Network recommends reducing enoxaparin to 30 mg subcutaneously once daily 1
• UFH is considered the agent of choice for patients with renal impairment as it's primarily metabolized by the liver 3, 4

Obesity

• For patients with BMI >30 kg/m², the American College of Cardiology recommends considering intermediate doses of enoxaparin (40 mg subcutaneously every 12 hours) or weight-based dosing (0.5 mg/kg subcutaneously every 12 hours) 1

Cancer Patients

• The National Comprehensive Cancer Network recommends UFH 5000 IU subcutaneously every 8 hours as the regimen for VTE prophylaxis in cancer patients 3, 4
• For long-term prophylaxis in cancer patients, the American Heart Association recommends LMWH over warfarin 5
• Dalteparin 200 IU/kg subcutaneously daily for 1 month, then 150 IU/kg subcutaneously daily for extended prophylaxis is recommended for cancer patients 2

Clinical Considerations and Pitfalls

• The American College of Cardiology recommends starting enoxaparin 2-4 hours preoperatively or 10-12 hours preoperatively for surgical patients 1
• Administering anticoagulants too close to neuraxial anesthesia increases the risk of spinal hematoma 1
• Routine monitoring of anti-Xa levels is not required for most patients on prophylactic doses, but consideration should be given to patients with extreme body weights or renal impairment 6, 1
• When transitioning to warfarin for long-term anticoagulation, the American Heart Association recommends overlapping parenteral anticoagulant with warfarin for at least 5 days and until INR ≥2.0 for at least 24 hours 5

Heparin 3000 Units 8 Hourly for Venous Thromboembolism Prophylaxis

Primary Indications

• The American College of Chest Physicians recommends VTE prophylaxis in patients with increased bleeding risk where standard 5000 unit dosing may be inappropriate, with a strength of evidence based on clinical trials 7, 8
• The National Comprehensive Cancer Network suggests thromboprophylaxis in patients with renal impairment where low molecular weight heparins (LMWHs) are contraindicated, with moderate evidence 9, 8

Dosing Considerations

Weight-Based Considerations

• The American Heart Association recommends standard prophylactic dosing of unfractionated heparin (UFH) is typically 5000 units every 8-12 hours, with high evidence 10
• Three times daily dosing provides more consistent anticoagulant effect compared to twice daily dosing, with moderate evidence 7, 10

Advantages of This Regimen

• The National Comprehensive Cancer Network notes that UFH is primarily metabolized by the liver, making it suitable for patients with renal impairment, with low evidence 9
• The National Comprehensive Cancer Network suggests that UFH can be used when LMWHs are contraindicated (e.g., in patients with history of heparin-induced thrombocytopenia), with moderate evidence 8, 9

Clinical Context

• The National Comprehensive Cancer Network recommends using UFH primarily in inpatient settings for medical and surgical patients at risk for VTE, with high evidence 8, 10
• The American College of Chest Physicians suggests that for surgical patients, prophylaxis should be continued for at least 7-10 days, with moderate evidence 8

Alternative Prophylactic Options

• The American College of Chest Physicians recommends UFH 5000 units subcutaneously every 8 hours for standard-weight patients, with high evidence 7, 8
• The Journal of Clinical Oncology suggests that for patients with normal renal function, LMWHs such as enoxaparin 40 mg daily or dalteparin 5000 units daily are alternative options, with moderate evidence 11
• The Journal of Clinical Oncology recommends that for patients with cancer, LMWH is generally preferred over UFH unless contraindicated, with high evidence 11, 12

Heparin Dosing for DVT Prophylaxis in Patients > 75 Years

Standard Prophylactic Dosing

Age‑Related Pharmacokinetics

Monitoring Requirements

Duration of Prophylaxis

Renal Impairment Considerations

Bleeding‑Risk Management

Therapeutic vs. Prophylactic Dosing

Alternative Anticoagulants (When UFH Is Contraindicated)